A K Wallin

Summary

Affiliation: Lund University
Country: Sweden

Publications

  1. pmc Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Neuropsychiatr Dis Treat 7:565-76. 2011
  2. pmc Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    BMC Neurol 12:134. 2012
  3. pmc Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
    Cecilia M Persson
    Department of Clinical Sciences in Malmo, Clinical Memory Research Unit, Lund University, Lund, Sweden
    BMC Neurol 9:7. 2009
  4. pmc Predictors of long-term cognitive outcome in Alzheimer's disease
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, SE 205 02 Malmo, Sweden
    Alzheimers Res Ther 3:23. 2011
  5. doi request reprint Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    A K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Int J Geriatr Psychiatry 24:638-47. 2009
  6. ncbi request reprint Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
  7. doi request reprint CSF biomarkers predict a more malignant outcome in Alzheimer disease
    A K Wallin
    Malmo University Hospital, SE 205 02 Malmo, Sweden
    Neurology 74:1531-7. 2010
  8. ncbi request reprint CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival
    A K Wallin
    Department of Psychiatry, Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Dement Geriatr Cogn Disord 21:131-8. 2006
  9. ncbi request reprint Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy
    A K Wallin
    Department of Psychiatry, Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Dement Geriatr Cogn Disord 18:197-206. 2004
  10. doi request reprint Long-term rivastigmine treatment in a routine clinical setting
    L Minthon
    Neuropsychiatric Clinic, Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Acta Neurol Scand 119:180-5. 2009

Detail Information

Publications10

  1. pmc Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Neuropsychiatr Dis Treat 7:565-76. 2011
    ..This study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of response and adherence to treatment...
  2. pmc Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    BMC Neurol 12:134. 2012
    ..The aim of this study was to identify the socio-demographic and clinical factors that affect the functional response after 6 months of ChEI therapy...
  3. pmc Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil
    Cecilia M Persson
    Department of Clinical Sciences in Malmo, Clinical Memory Research Unit, Lund University, Lund, Sweden
    BMC Neurol 9:7. 2009
    ..The objective was to identify separate cognitive domains in the standard assessment tools (MMSE, ADAS-Cog) and analyze the process of decline within domains during three years in Alzheimer's disease (AD) patients with donepezil treatment...
  4. pmc Predictors of long-term cognitive outcome in Alzheimer's disease
    Carina Wattmo
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, SE 205 02 Malmo, Sweden
    Alzheimers Res Ther 3:23. 2011
    ..The objective of this study was to describe the longitudinal cognitive outcome in Alzheimer's disease (AD) and analyze factors that affect the outcome, including the impact of different cholinesterase inhibitors (ChEI)...
  5. doi request reprint Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
    A K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmo, Sweden
    Int J Geriatr Psychiatry 24:638-47. 2009
    ..A secondary objective was to evaluate whether treatment with ChEI changed progression...
  6. ncbi request reprint Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
    ..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
  7. doi request reprint CSF biomarkers predict a more malignant outcome in Alzheimer disease
    A K Wallin
    Malmo University Hospital, SE 205 02 Malmo, Sweden
    Neurology 74:1531-7. 2010
    ..To investigate if patterns of CSF biomarkers (T-tau, P-tau, and Abeta42) can predict cognitive progression, outcome of cholinesterase inhibitor (ChEI) treatment, and mortality in Alzheimer disease (AD)...
  8. ncbi request reprint CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival
    A K Wallin
    Department of Psychiatry, Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Dement Geriatr Cogn Disord 21:131-8. 2006
    ..011) than those who were still alive. Patients who had died in a 6-year follow-up had significantly lower levels of Abeta42 (p = 0.034) and higher levels of T-tau (p = 0.041) than patients still alive...
  9. ncbi request reprint Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy
    A K Wallin
    Department of Psychiatry, Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Dement Geriatr Cogn Disord 18:197-206. 2004
    ..Response to tacrine treatment at 6 or 12 months was found to predict a prolonged time until nursing home placement. No predictors for a positive treatment response could be identified at baseline...
  10. doi request reprint Long-term rivastigmine treatment in a routine clinical setting
    L Minthon
    Neuropsychiatric Clinic, Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Acta Neurol Scand 119:180-5. 2009
    ..The aim of the study was to observe the effects of long-term rivastigmine treatment in patients with mild to moderate Alzheimer's disease (AD) in a routine clinical setting...